Insulin resistance and other features of the metabolic syndrome are increasingly recognized for their effects on cognitive health. To ascertain mechanisms by which this occurs, we fed mice a very high fat diet (60% kcal by fat) for 17 days or a moderate high fat diet (HFD, 45% kcal by fat) for 8 weeks and examined changes in brain insulin signaling responses, hippocampal synaptodendritic protein expression, and spatial working memory. Compared to normal control diet mice, cerebral cortex tissues of HFD mice were insulin-resistant as evidenced by failed activation of Akt, S6 and GSK3β with ex-vivo insulin stimulation. Importantly, we found that expression of brain IPMK, which is necessary for mTOR/Akt signaling, remained decreased in HFD mice upon activation of AMPK. HFD mouse hippocampus exhibited increased expression of serine-phosphorylated insulin receptor substrate 1 (IRS1-pS 616 ), a marker of insulin resistance, as well as decreased expression of PSD-95, a scaffolding protein enriched in post-synaptic densities, and synaptopodin, an actin-associated protein enriched in spine apparatuses. Spatial working memory was impaired as assessed by decreased spontaneous alternation in a Tmaze. These findings indicate that HFD is associated with telencephalic insulin resistance and deleterious effects on synaptic integrity and cognitive behaviors.
Introduction "Metabolic syndrome" or "insulin resistance syndrome," are terms for a still evolving disorder that clusters insulin resistance, impaired glucose regulation, dyslipidemia, abdominal obesity, and hypertension with risk for cardiovascular disease and type II diabetes (Kassi et al., 2011; Reaven, 2011) There is growing recognition that insulin resistance, type II diabetes and other features of the metabolic syndrome are also associated with brain disorders including Alzheimer's disease and other neurodegenerative dementias (Baker et al., 2010; Biessels et al., 2006; Correia et al., 2011; de la Monte, 2009; Haan, 2006; Neumann et al., 2008; Profenno et al., 2010; Zhao and Townsend, 2009) depression (Amato et al., 1996; Knol et al., 2006; Okamura et al., 2000; Pan et al., 2010; Pouwer et al., 2003; Weber-Hamann et al., 2006) , and possibly schizophrenia, bipolar and anxiety disorders (Heppner et al., 2009; McEvoy et al., 2005; McIntyre et al., 2010) .
The nature of these associations is complex. In Alzheimer's disease (AD), research has described on the one hand that people with clinical AD, apolipoprotein E ε4 genotype and/or amyloid-β biomarkers exhibit abnormal insulin levels and insulin metabolism, while on the other hand, a history of type 2 diabetes and even normoglycemic insulin resistance increases risk for subsequent AD (Baker et al., 2010; Biessels et al., 2006; Correia et al., 2011; de la Monte, 2009; Haan, 2006; Neumann et al., 2008; Profenno et al., 2010; Schrijvers et al.; Zhao and Townsend, 2009 ). We recently reported direct evidence of brain insulin resistance in humans with mild cognitive impairment and AD as well as extensive abnormalities in the activation status of numerous constituents of the insulin-insulin receptor substrate-1 (IRS-1)-PI3k-AktmTOR and GSK3 pathways (Talbot et al., 2012) . Such studies have stimulated interest in a role for insulin and other anti-diabetes medications for treatment of AD.
Reciprocal links between T2D and psychiatric disorders have also been described. For instance, depression increases risk for subsequent development of T2D (Knol et al., 2006) while the presence of T2D increases risk for incident depression. However, understanding of metabolic syndrome's association with psychiatric disorders is more complicated than with AD, as these are frequently confounded by poor health status and medications, especially atypical antipsychotics which in themselves induce obesity and the metabolic syndrome (De Hert et al., 2012 
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